Elevance Health amends bylaws to align with SEC universal proxy rules

Elevance Health, Inc.

Shareholders must provide detailed Schedule 13D-type disclosures on plans, agreements with respect to company securities.
Nominating shareholder must certify compliance with Exchange Act Rule 14a-19 at least 10 days before meeting.
Shareholders soliciting proxies must use a proxy card color other than white (reserved for Board).
Number of nominees a shareholder may propose is capped at number of directors to be elected.
Votes for any nominee not complying with bylaws or Rule 14a-19 may be disregarded.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Elevance Health, Inc.: Amended bylaws to update procedural and informational requirements for director nominations in response to SEC universal proxy rules (effective 2023-10-04).

Change: bylaw amendment
Effective: 2023-10-04

Exact text from the filing

On October 4, 2023, the Board of Directors (the “Board”) of Elevance Health, Inc. (the “Company”) approved the amendment of the Company’s Bylaws (as so amended, the “Bylaws”) to, among other things, update procedural and informational requirements applicable to director nominations submitted by shareholders in light of the Securities and Exchange Commission’s adoption of “universal proxy” rules as set forth in Rule 14a-19 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

View on SEC.gov

Browse all governance changes →

Elevance Health, Inc. filing history →

Source: SEC EDGAR

accession 0001156039-23-000106

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.